Evidence of recurrent gene fusions in common epithelial tumors

Trends in Molecular Medicine

Volumn 12, Issue 11, 2006, Pages 529-536

  Kumar Sinha, Chandan ^a   Tomlins, Scott A ^b   Chinnaiyan, Arul M ^b  

^a Research and Education in Cancer   (India)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; CORE BINDING FACTOR; DNA BINDING PROTEIN; ENZYME INHIBITOR; HIGH MOBILITY GROUP A2 PROTEIN; HISTONE ACETYLTRANSFERASE; IMATINIB; MITOGEN ACTIVATED PROTEIN KINASE; NEUROTROPHIC TYROSINE KINASE RECEPTOR TYPE 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN RET; RAS PROTEIN; RETINOIC ACID RECEPTOR; SERINE PROTEINASE; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR ETS; TRANSCRIPTION FACTOR PAX8; TRANSCRIPTION FACTOR RUNX1; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; B CELL LEUKEMIA; CANCER GENETICS; CANCER PATIENT; CHROMOSOME ABERRATION; CHROMOSOME BANDING PATTERN; CHROMOSOME STRUCTURE; CHRONICITY; CYTOGENETICS; DNA MODIFICATION; EPIGENETICS; EPITHELIUM TUMOR; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE DELETION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE FUSION; GENE OVEREXPRESSION; GENETIC POLYMORPHISM; HEMATOLOGIC MALIGNANCY; HUMAN; LEUKEMIA; MOLECULAR GENETICS; ONCOGENE; ONCOGENE NEU; PLEOMORPHIC ADENOMA GENE 1; POINT MUTATION; PROSTATE CANCER; PROTEIN VARIANT; REVIEW; SOFT TISSUE CANCER; THYROID CARCINOMA;

CARCINOMA; CHROMOSOME ABERRATIONS; ENHANCER ELEMENTS (GENETICS); GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE FUSION; HUMANS; LEUKEMIA; MALE; MODELS, GENETIC; NEOPLASMS, GLANDULAR AND EPITHELIAL; ONCOGENE PROTEINS, FUSION; PROMOTER REGIONS (GENETICS); PROSTATIC NEOPLASMS;

EID: 33750378672     PISSN: 14714914     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molmed.2006.09.005     Document Type: Review

References (76)

1. Futreal P.A., et al. A census of human cancer genes. Nat. Rev. Cancer 4 (2004) 177-183
2. Rabbitts T.H. Chromosomal translocations in human cancer. Nature 372 (1994) 143-149
3. Rowley J.D. Chromosome translocations: dangerous liaisons revisited. Nat. Rev. Cancer 1 (2001) 245-250
4. Baselga J., et al. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J. Clin. Oncol. 14 (1996) 737-744
5. Druker B.J., et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N. Engl. J. Med. 344 (2001) 1038-1042
6. Druker B.J., et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 344 (2001) 1031-1037
7. Tomlins S.A., et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310 (2005) 644-648
8. Nowell P.C., and Hungerford D.A. A minute chromosome in human chronic granulocytic leukemia. Science 132 (1960) 1497-1501
9. Nowell P.C., and Hungerford D.A. Chromosome studies in human leukaemia. II. Chronic granulocytic leukemia. J. Natl. Cancer Inst. 27 (1961) 1013-1035
10. Caspersson T., et al. Differential binding of alkylating fluorochromes in human chromosomes. Exp. Cell Res. 60 (1970) 315-319
11. Rowley J.D. Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 243 (1973) 290-293
12. Lugo T.G., et al. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 247 (1990) 1079-1082
13. Daley G.Q., et al. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 247 (1990) 824-830
14. Rowley J.D. Identification of a translocation with quinacrine fluorescence in a patient with acute leukemia. Ann. Genet. 16 (1973) 109-112
15. Hiebert S.W., et al. Transcriptional regulation by the t(8;21) fusion protein, AML-1/ETO. Curr. Top. Microbiol. Immunol. 211 (1996) 253-258
16. Frank R., et al. The AML1/ETO fusion protein blocks transactivation of the GM-CSF promoter by AML1B. Oncogene 11 (1995) 2667-2674
17. Wang J., et al. ETO, fusion partner in t(8;21) acute myeloid leukemia, represses transcription by interaction with the human N-CoR/mSin3/HDAC1 complex. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 10860-10865
18. Goddard A.D., et al. Characterization of a zinc finger gene disrupted by the t(15;17) in acute promyelocytic leukemia. Science 254 (1991) 1371-1374
19. Salomoni P., and Pandolfi P.P. The role of PML in tumor suppression. Cell 108 (2002) 165-170
20. Grignani F., et al. The acute promyelocytic leukemia-specific PML-RAR α fusion protein inhibits differentiation and promotes survival of myeloid precursor cells. Cell 74 (1993) 423-431
21. Grignani F., et al. Fusion proteins of the retinoic acid receptor-α recruit histone deacetylase in promyelocytic leukaemia. Nature 391 (1998) 815-818
22. Lin R.J., et al. Role of the histone deacetylase complex in acute promyelocytic leukaemia. Nature 391 (1998) 811-814
23. Cimino G., et al. ALL1 gene alterations in acute leukemia: biological and clinical aspects. Haematologica 83 (1998) 350-357
24. Downing J.R., and Look A.T. MLL fusion genes in the 11q23 acute leukemias. Cancer Treat. Res. 84 (1996) 73-92
25. Redner R.L., et al. Chromatin remodeling and leukemia: new therapeutic paradigms. Blood 94 (1999) 417-428
26. Claxton D.F., et al. Detection of fusion transcripts generated by the inversion 16 chromosome in acute myelogenous leukemia. Blood 83 (1994) 1750-1756
27. Cremer T., et al. Detection of chromosome aberrations in metaphase and interphase tumor cells by in situ hybridization using chromosome-specific library probes. Hum. Genet. 80 (1988) 235-246
28. Gray J.W., and Pinkel D. Molecular cytogenetics in human cancer diagnosis. Cancer 69 (1992) 1536-1542
29. Schrock E., et al. Multicolor spectral karyotyping of human chromosomes. Science 273 (1996) 494-497
30. Speicher M.R., et al. Karyotyping human chromosomes by combinatorial multi-fluor FISH. Nat. Genet. 12 (1996) 368-375
31. Mitelman F. Recurrent chromosome aberrations in cancer. Mutat. Res. 462 (2000) 247-253
32. Mitelman F., et al. Fusion genes and rearranged genes as a linear function of chromosome aberrations in cancer. Nat. Genet. 36 (2004) 331-334
33. Knezevich S.R., et al. A novel ETV6-NTRK3 gene fusion in congenital fibrosarcoma. Nat. Genet. 18 (1998) 184-187
34. Tognon C., et al. Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma. Cancer Cell 2 (2002) 367-376
35. Eguchi M., et al. Fusion of ETV6 to neurotrophin-3 receptor TRKC in acute myeloid leukemia with t(12;15)(p13;q25). Blood 93 (1999) 1355-1363
36. Rubin B.P., et al. Congenital mesoblastic nephroma t(12;15) is associated with ETV6-NTRK3 gene fusion: cytogenetic and molecular relationship to congenital (infantile) fibrosarcoma. Am. J. Pathol. 153 (1998) 1451-1458
37. Tognon C., et al. The chimeric protein tyrosine kinase ETV6-NTRK3 requires both Ras-Erk1/2 and PI3-kinase-Akt signaling for fibroblast transformation. Cancer Res. 61 (2001) 8909-8916
38. Wai D.H., et al. The ETV6-NTRK3 gene fusion encodes a chimeric protein tyrosine kinase that transforms NIH3T3 cells. Oncogene 19 (2000) 906-915
39. Pierotti M.A. Chromosomal rearrangements in thyroid carcinomas: a recombination or death dilemma. Cancer Lett. 166 (2001) 1-7
40. Nikiforov Y.E. RET/PTC rearrangement in thyroid tumors. Endocr. Pathol. 13 (2002) 3-16
41. Bongarzone I., et al. RET/NTRK1 rearrangements in thyroid gland tumors of the papillary carcinoma family: correlation with clinicopathological features. Clin. Cancer Res. 4 (1998) 223-228
42. Grieco M., et al. PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas. Cell 60 (1990) 557-563
43. Pierotti M.A., et al. Characterization of an inversion on the long arm of chromosome 10 juxtaposing D10S170 and RET and creating the oncogenic sequence RET/PTC. Proc. Natl. Acad. Sci. U. S. A. 89 (1992) 1616-1620
44. Sozzi G., et al. A t(10;17) translocation creates the RET/PTC2 chimeric transforming sequence in papillary thyroid carcinoma. Genes Chromosomes Cancer 9 (1994) 244-250
45. Fugazzola L., et al. Molecular and biochemical analysis of RET/PTC4, a novel oncogenic rearrangement between RET and ELE1 genes, in a post-Chernobyl papillary thyroid cancer. Oncogene 13 (1996) 1093-1097
46. Santoro M., et al. Molecular characterization of RET/PTC3; a novel rearranged version of the RET proto-oncogene in a human thyroid papillary carcinoma. Oncogene 9 (1994) 509-516
47. Klugbauer S., et al. Detection of a novel type of RET rearrangement (PTC5) in thyroid carcinomas after Chernobyl and analysis of the involved RET-fused gene RFG5. Cancer Res. 58 (1998) 198-203
48. Greco A., et al. Chromosome 1 rearrangements involving the genes TPR and NTRK1 produce structurally different thyroid-specific TRK oncogenes. Genes Chromosomes Cancer 19 (1997) 112-123
49. Greco A., et al. TRK-T1 is a novel oncogene formed by the fusion of TPR and TRK genes in human papillary thyroid carcinomas. Oncogene 7 (1992) 237-242
50. Greco A., et al. The DNA rearrangement that generates the TRK-T3 oncogene involves a novel gene on chromosome 3 whose product has a potential coiled-coil domain. Mol. Cell. Biol. 15 (1995) 6118-6127
51. Greco A., et al. Role of the TFG N-terminus and coiled-coil domain in the transforming activity of the thyroid TRK-T3 oncogene. Oncogene 16 (1998) 809-816
52. Borrello M.G., et al. The full oncogenic activity of Ret/ptc2 depends on tyrosine 539, a docking site for phospholipase Cγ. Mol. Cell. Biol. 16 (1996) 2151-2163
53. McIver, B. and. (2004) The PAX8/PPARγ fusion oncogene as a potential therapeutic target in follicular thyroid carcinoma. Curr. Drug Targets Immune Endocr. Metabol. Disord. 4, 221-234
54. Giordano T.J., et al. Delineation, functional validation, and bioinformatic evaluation of gene expression in thyroid follicular carcinomas with the PAX8-PPARG translocation. Clin. Cancer Res. 12 (2006) 1983-1993
55. Meloni A.M., et al. Translocation (X;1) in papillary renal cell carcinoma. A new cytogenetic subtype. Cancer Genet. Cytogenet. 65 (1993) 1-6
56. Sidhar S.K., et al. The t(X;1)(p11.2;q21.2) translocation in papillary renal cell carcinoma fuses a novel gene PRCC to the TFE3 transcription factor gene. Hum. Mol. Genet. 5 (1996) 1333-1338
57. Weterman M.A., et al. Fusion of the transcription factor TFE3 gene to a novel gene, PRCC, in t(X;1)(p11;q21)-positive papillary renal cell carcinomas. Proc. Natl. Acad. Sci. U. S. A. 93 (1996) 15294-15298
58. Stenman G. Fusion oncogenes and tumor type specificity - insights from salivary gland tumors. Semin. Cancer Biol. 15 (2005) 224-235
59. Engleson J., et al. Midline carcinoma with t(15;19) and BRD4-NUT fusion oncogene in a 30-year-old female with response to docetaxel and radiotherapy. BMC Cancer 6 (2006) 69
60. French C.A., et al. BRD4-NUT fusion oncogene: a novel mechanism in aggressive carcinoma. Cancer Res. 63 (2003) 304-307
61. Mertens F., et al. Successful treatment of a child with t(15;19)-positive tumor. Pediatr. Blood Cancer (2006) 10.1002/pbc.20755
62. French C.A., et al. Midline carcinoma of children and young adults with NUT rearrangement. J. Clin. Oncol. 22 (2004) 4135-4139
63. Haruki N., et al. Cloned fusion product from a rare t(15;19)(q13.2;p13.1) inhibit S phase in vitro. J. Med. Genet. 42 (2005) 558-564
64. Gorunova L., et al. Cytogenetic analysis of pancreatic carcinomas: intratumor heterogeneity and nonrandom pattern of chromosome aberrations. Genes Chromosomes Cancer 23 (1998) 81-99
65. Johansson B., et al. Primary vs. secondary neoplasia-associated chromosomal abnormalities-balanced rearrangements vs. genomic imbalances?. Genes Chromosomes Cancer 16 (1996) 155-163
66. Fine B.M., et al. Gene expression patterns associated with recurrent chromosomal translocations in acute lymphoblastic leukemia. Blood 103 (2004) 1043-1049
67. Kauraniemi P., et al. New amplified and highly expressed genes discovered in the ERBB2 amplicon in breast cancer by cDNA microarrays. Cancer Res. 61 (2001) 8235-8240
68. Rhodes D.R., et al. ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia 6 (2004) 1-6
69. Oikawa T., and Yamada T. Molecular biology of the Ets family of transcription factors. Gene 303 (2003) 11-34
70. Afar D.E., et al. Catalytic cleavage of the androgen-regulated TMPRSS2 protease results in its secretion by prostate and prostate cancer epithelia. Cancer Res. 61 (2001) 1686-1692
71. Jacquinet E., et al. Cloning and characterization of the cDNA and gene for human epitheliasin. Eur. J. Biochem. 268 (2001) 2687-2699
72. Lin B., et al. Prostate-localized and androgen-regulated expression of the membrane-bound serine protease TMPRSS2. Cancer Res. 59 (1999) 4180-4184
73. Yoshimoto M., et al. Three-color FISH analysis of TMPRSS2/ERG fusions in prostate cancer indicates that genomic microdeletion of chromosome 21 is associated with rearrangement. Neoplasia 8 (2006) 465-469
74. Soller M.J., et al. Confirmation of the high frequency of the TMPRSS2/ERG fusion gene in prostate cancer. Genes Chromosomes Cancer 45 (2006) 717-719
75. Tomlins S.A., et al. TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer. Cancer Res. 66 (2006) 3396-3400
76. Kroll T.G. Molecular events in follicular thyroid tumors. Cancer Treat. Res. 122 (2004) 85-105